. 2025 Apr 16;63(5):e01893-24. doi: 10.1128/jcm.01893-24

TABLE 2.

MIC ranges (including MIC₅₀ and MIC₉₀) and categorization of susceptibility results of the isolates^e^,^f

Antibiotic	Method	MIC distribution						Categorical distribution
		OXA-48-like			Controls			OXA-48-like						Controls
		MIC₅₀	MIC₉₀	P^b	MIC₅₀	MIC₉₀	P ^b	S	I	R	%R	Total^d	P ^c	S	I	R	%R	Total^d	P^c
Ertapenem	Broth microdilution	2	16	–	2	16	–	14	–	93	86.9	107	–	37	–	105	73.9	142	–
	Disk diffusion	–	–	–	–	–	–	7	–	100	93.5	107	0.168	24	–	118	83.1	142	0.082
	Gradient test (ETEST)	2	≥32	0.974	2	≥32	0.625	16	–	91	85.0	107	0.843	35	–	107	75.4	142	0.891
	VITEK 2 AST-N223	4	≥8	<0.001	4	≥8	0.006	10	–	94	90.4	104	0.658	23	–	101	81.5	124	0.352
	VITEK 2 AST-N428	2	≥8	0.024	4	≥8	0.091	12	–	94	88.7	106	0.834	36	–	106	74.6	142	1.00
	VITEK 2 AST-N432	2	≥8	0.006	4	≥8	0.021	13	–	94	87.9	107	1.00	31	–	111	78.2	142	0.486
Imipenem^a	Broth microdilution	2	8	–	0.5	4	–	83	11	13	12.1	107	–	125	7	10	7.0	142	–
	Disk diffusion	–	–	–	–	–	–	52	30	25	23.4	107	0.049	118	10	14	9.9	142	0.522
	Gradient test (ETEST)	1	16	0.924	1	8	0.062	73	13	21	19.6	107	0.190	115	9	18	12.7	142	0.163
	VITEK 2 AST-N223	2	≥16	0.065	1	8	0.448	74	9	19	18.6	102	0.108	103	3	13	10.9	119	0.660
	VITEK 2 AST-N428	1	4	0.813	1	4	0.785	75	22	8	7.6	105	0.357	125	7	8	5.7	140	0.807
Meropenem	Broth microdilution	1	16	–	0.5	8	–	84	12	11	10.3	107	–	112	26	4	2.8	142	–
	Disk diffusion	–	–	–	–	–	–	67	28	12	11.2	107	1.00	99	32	11	7.7	142	0.111
	Gradient test (ETEST)	1	≥32	0.216	0.5	8	0.589	86	9	12	11.2	107	1.00	111	18	13	9.2	142	0.045
	VITEK 2 AST-N223	2	≥16	0.007	1	4	0.240	71	20	13	12.5	104	0.828	96	23	5	4.0	124	1.00
	VITEK 2 AST-N428	2	≥16	0.009	1	4	0.813	74	20	13	12.1	107	0.828	116	21	5	3.5	142	1.00
	VITEK 2 AST-N432	2	≥16	0.004	1	4	0.531	67	29	11	10.3	107	1.00	114	23	5	3.5	142	1.00

^{^a}

Imipenem is not available on the AST-N432 card.

^{^b}

Comparison with MIC distribution of BMD (Mann-Whitney U test).

^{^c}

Comparison with R frequency of BMD (Pearson’s χ² test).

^{^d}

Numbers are given based on the determined MIC from the respective test. While results were obtained for all isolates by BMD, ETEST, and DD, VITEK 2 MICs for some isolates could not be determined by N223/N428 cards.

^{^e}

EUCAST clinical breakpoints: ertapenem, MIC: ≤0.5 and >0.5, zone diameter: ≥23 and <23; imipenem, MIC: ≤2 and >4, zone diameter: ≥22 and <19; meropenem, MIC: ≤2 and >8, zone diameter: ≥22 and <16 (22).

^{^f}

S, susceptible; I, susceptible, increased exposure; R, resistant. "-" represents not applicable (N/A). Bolded when P<0.05.